Retour aux projets

14011.2 PFLS-LS

14011.2 PFLS-LS

Résumé

Development of an organotypic high-throughput screening assay kit to determine predictability of anti-cancer drugs in 3D QGel

Textes supplémentaires

Abstract

This project brings together the start-up company QGel and academic cancer and matrix|biology experts in order to develop proven QGel technology into a 3D cell-based highthroughput|assay kit for primary patient-derived cancer cells. Commercially available anticancer|drugs will be tested on these tumor models grown in vitro with QGel technology.|Based on indications by cancer experts, QGel drug-tumor response data are collected and|compared to clinical data of these drugs.

Participants

Colin Sanctuary

Wirtschaftspartner

colin.sanctuary@qgelbio.com

QGel SA Colin Sanctuary Bâtiment C / EPFL Innovation Park 1015 Lausanne VD CH

Matthias Lutolf

Kontaktperson

matthias.lutolf@epfl.ch

EPFL SV IBI LSCB Matthias Lutolf Station 15, Bâtiment Al 1109 1015 Lausanne VD CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2013-05-31
Date de fin
2017-03-31
Coûts totaux approuvés
CHF 395600.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • P004 Biochemistry, Metabolism 100.0%